Inno-Gene SA
WSE:IGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Inno-Gene SA
Total Liabilities & Equity
Inno-Gene SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Inno-Gene SA
WSE:IGN
|
Total Liabilities & Equity
zł5.5m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-8%
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Total Liabilities & Equity
zł16.4m
|
CAGR 3-Years
245%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Total Liabilities & Equity
zł403.2m
|
CAGR 3-Years
20%
|
CAGR 5-Years
8%
|
CAGR 10-Years
32%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Total Liabilities & Equity
zł642.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Inno-Gene SA
Glance View
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
See Also
What is Inno-Gene SA's Total Liabilities & Equity?
Total Liabilities & Equity
5.5m
PLN
Based on the financial report for Jun 30, 2024, Inno-Gene SA's Total Liabilities & Equity amounts to 5.5m PLN.
What is Inno-Gene SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-8%
Over the last year, the Total Liabilities & Equity growth was -41%. The average annual Total Liabilities & Equity growth rates for Inno-Gene SA have been -34% over the past three years , -22% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
